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Abstract  
There is mounting evidence linking traumatic brain injury (TBI) to neurodegeneration. 
Clusterin (Apoliporotein J or ApoJ) is a complement inhibitor that appears to have a 
neuroprotective effect in response to tissue damage and has been reported to be upregulated 
in Alzheimer’s disease.  Here we investigated the time course and cellular expression pattern 
of clusterin in human TBI. Tissue from 32 patients with TBI of varying survival times, (from 
under 30 minutes to ten months), was examined using immunohistochemistry for clusterin 
alongside other markers of neurodegeneration and neuroinflammation. TBI cases were 
compared to ischaemic brain damage, Alzheimer’s disease and controls. Double 
immunofluorescence was carried out in order to examine cellular expression. Clusterin was 
initially expressed in an axonal location less than 30 minutes following TBI and increased in 
intensity and the  frequency of deposits with increasing survival time up to 24 hours, after 
which it appeared to reduce in intensity but was still  evident several weeks after injury. 
Clusterin  was  first evident in astrocytes after  45 minutes, being increasingly  seen  up to  48 
hours but  remaining intense in TBI cases with long survival times. Our results suggest 
clusterin plays a role in modulating the inflammatory response of acute and chronic TBI and 
that it is a useful marker for TBI, particularly in cases with short survival times. Its prominent 
accumulation in astrocytes, alongside a mounting inflammatory response and activation of 
microglial cells supports a potential role in the neurodegenerative changes that occur as a 
result of TBI.  
Key words:  head injury, clusterin, neurodegeneration, astrocytes, timing   
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Introduction 
Clusterin, also known as Apolipoprotein J (ApoJ), is a highly conserved ubiquitous 
glycoprotein expressed in mammalian cells. It is a stress-induced chaperone which is 
normally secreted, however, in conditions of cellular stress it can be transported to the 
cytoplasm where it binds to Bax protein and inhibits neuronal apoptosis 
1
. Additionally 
clusterin is a well-known complement inhibitor, binding to C5b-7 component and inhibiting 
the formation and membrane binding of MAC (membrane attack complex).  Expression of 
clusterin is mainly seen in astrocytes and is also prominent in pyramidal cells of the 
hippocampus and the Purkinje cell layer of the cerebellum 
2
. Several studies have 
demonstrated that clusterin is involved in the immune response, for example, Interleukins-1B 
and -2 have both been shown to increase the expression of clusterin in astrocytes 
3
.  
The expression of the Clusterin (CLU) gene has been shown to be up-regulated by a 
multitude of stress and cellular injuries, as well as cellular growth, differentiation and ageing. 
Gene expression has also been shown to be increased in several disease states, including 
neurodegeneration, atherosclerosis and cancer 
4
.  
It has been known for a number of years that clusterin expression is increased in brain tissue 
from patients with Alzheimer’s disease (AD) and it was subsequently observed that clusterin 
can bind amyloid-β (Aβ) peptides and prevent their fibrillization 
5
. Clusterin is also involved 
in the clearance of amyloid-β peptides and fibrils and, by its effect as a complement inhibitor, 
can suppress the complement activation seen in AD; moreover it appears that the 
accumulation of misfolded proteins, such as seen in neurodegenerative diseases, can induce 
clusterin expression 
1
. Recently variants within the CLU gene were identified as a 
susceptibility factor for late onset AD by a large genome-wide association study 
6
. Indeed, 
clusterin protein levels are increased in amyloid-based mouse models of AD and early in 
disease in blood from human patients 
7, 8
.  In AD post-mortem tissue, clusterin has been 
shown to be present in neuritic plaques, neuropil threads, cerebrovascular deposits and, to a 
lesser extent, in diffuse amyloid plaques 
9
. A recent study 
10
 demonstrated that amyloid-β 
rapidly targets the clusterin protein, causing its intracellular accumulation, with the authors 
concluding that amyloid-induced neurotoxicity is via the clusterin dependent induction of 
Dickkopf-1 (Dkk1), which then drives the Wnt-planar cell polarity pathway to increase the 
expression of genes involved in the neurodegenerative process.  
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Head injury causes an acute inflammatory response, which can last minutes, days or even 
months. An immediate severe response occurs in order to minimise tissue damage, which 
involves activation of the complement system 
11
 (this may actually also contribute to further 
“secondary damage”). However, research suggests head injuries can also cause a long-term 
degenerative process similar to that observed in neurodegenerative diseases 
12-16
.  
Up-regulation of Apolipoproteins (including clusterin) in reactive astrocytes and neurons 
modulates the inflammatory response found shortly after CNS insults, such as traumatic brain 
injury (TBI). Previous studies have shown expression of clusterin in animal models of head 
injury, with an increase in clusterin being seen in the first 2 days after injury and then a return 
to baseline by 2 weeks which is followed by a second increase lasting up to 6 months 
17
. Both 
clusterin and ApoE were found to co-localise with amyloid-β accumulation in neurons and 
astrocytes 1-6 months after injury, suggesting clusterin may play a role in the acute response 
to trauma since clusterin is involved in suppression of complement activation it may have a 
protective role to prevent secondary damage and then re-emerge long after the initial insult, 
potentially modulating neurodegenerative changes. 
In this study we have investigated the time course and cellular expression of clusterin in 
human TBI. 
 
Materials and Methods 
Post-mortem tissue samples 
Brain tissue samples in 10% formalin-fixed, paraffin-embedded tissue blocks were available 
from the London Neurodegenerative Diseases Brain Bank (King’s College London, UK). 
Consent for autopsy, neuropathological assessment and research were obtained and all studies 
were carried out under the ethical approval of the tissue bank. Block taking for histological 
and immunohistochemical studies and neuropathological assessment for neurodegenerative 
diseases was performed in accordance with standard criteria. 
A total of 32 cases of traumatic brain injury were investigated (mean 43±20yr) with varying 
survival times from the initial injury (see Table 1 for case details). All these cases suffered a 
closed head injury with no significant intra-cranial haemorrhage. Although cases with 
significant focal cerebral lesions (such as contusions) were excluded where possible   
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occasional cases had small thin films of subarchnoid haemorrhage or mild extradural or 
subdural haematomas  (Table 2). Occasional small contusions were noted  and  a small 
number of brains revealed at most mild cerebral swelling (Table 2).  Nine cases were reported 
as having a survival of less than 60 minutes; five cases had a survival time of 1-12 hours; 
three cases had a survival time of 13-24 hours; four cases had a survival time of 25-48 hours; 
seven cases had a survival time of 8-49 days and four cases showed a survival time of 6-10 
months.The causes of death in cases HI1-28 were severe head injury. In addition in cases 
HI25 and 27 there were additional ischaemic changes contributing (with some small cerebral 
infarcts in HI27). Case HI29 later died of drowning, cases  HI30 and 31  suffered severe 
epileptic fits, and case HI32 died from asphyxia due to hanging.  
Four cases of Alzheimer’s disease were also investigated (mean 84±8yr). These cases had 
both a clinical diagnosis of Alzheimer’s disease and clear pathological evidence of 
Alzheimer’s disease with no other pathology. These cases were used as a positive control for 
the presence of clusterin (see Table 3). 
Three cases of ischaemic damage to the brain were selected from patients with hypovolemic 
shock after a stab wound, intestinal bleeding and cardiac arrest (mean 44±17yr, Table 3). 
Detailed post mortem examination was carried out on these cases and it was demonstrated 
that there was no other pathological process or disease affecting the body or the brain. 
Five control cases were also selected (mean 38±13yr, Table  3). All these cases had 
previously been comprehensively examined by histological examination and 
immunohistochemistry and showed no evidence of any pathological process. 
In all the studied cases, the following regions were examined: frontal lobe, temporal lobe, 
hippocampus, corpus callosum, basal ganglia, midbrain and pons. Blocks were selected 
distant from focal pathology such as small contusions and haemorrhage.  
Immunohistochemistry: 
 The immunohistochemistry technique for clusterin was carried out as per previously 
published protocols 
18
. In brief, sections of 7µm thickness were cut from the paraffin-
embedded tissue blocks, deparaffinised in xylene, endogenous peroxidase blocked by 
immersion in 2.5% H2O2 in methanol and immunohistochemistry performed. To enhance 
antigen retrieval, sections were kept in citrate buffer for 10 minutes following microwave 
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treatment. After blocking in normal swine serum (DAKO, Cambridgeshire, UK), clusterin 
antibody (AbCam, ab69644) was applied at 1:500 overnight at 4°C.  
Following washes, sections were incubated with biotinylated secondary antibody (DAKO), 
followed by avidin:biotinylated enzyme complex (Vectastain Elite ABC kit, Vector 
Laboratories, Peterborough, UK). Finally sections were incubated for 5–10 min with 
0.5 mg/mL 3,3′-diaminobenzidine chromogen (Sigma-Aldrich Company Ltd, Dorset UK) in 
Tris-buffered saline (pH 7.6) containing 0.05% H2O2. Sections were counterstained with 
Harris’ haematoxylin and immunostaining analysed using a Leica microscope (Leica, 
Wetzlar, Germany).  
Additionally, immunohistochemistry with the following antibodies was carried out during the 
diagnostic assessment of all cases examined (except for  GFAP, S100, and C5b-9, which 
were applied to cases HI12, 13, 15, 20, 22, 24, 26, 27, 30, 31  C4 and C5) using the Leica 
BONDMAX™ (Leica Biosystems, Wetzlar, Germany): Aβ ( clone 4G8; 1:1000, Chemicon, 
Temecula, CA), βAPP (clone 22C11; 1/10000, Chemicon, Temecula, CA), p62 (1/100, BD 
Biosciences, Erembodegem, Belgium), phosphorylated tau (clone AT-8; 1:500, Autogen 
Bioclear UK Ltd, Wiltshire, UK), phosphorylated pTDP-43 (pS409/410-2); 1:1500, Cosmo 
Bio Ltd, Tokyo, Japan), GFAP ( Z0334; 1:1000,  Dako,  Glostrup, Denmark ) Complement 
(MAC)-  C5b-9( Clone  aE11; 1:50 , Dako ), S100( Z0311;  1:1500, Dako ) CD68 (clone 
PGM1; 1:50, Dako). 
Double Immunofluorescence: 
To identify the cell types expressing clusterin and to investigate potential co-localisation of 
clusterin with βAPP, double immunofluorescence was carried out on a sub-set of cases (three 
cases of AD and six cases of head injury (three acute, three old)) (labelled 
§
  in Tables 1 and 
3). Healthy control tissue was also examined. The details of the antibodies and dilutions are 
given in Table 4.  
 The 7µm sections were cut from formalin fixed paraffin embedded blocks, dewaxed in 
xylene and dehydrated in 99% industrial methylated spirit. Sections were then pretreated by 
microwaving in citrate buffer and blocked using normal goat serum (1:10 for 45min). 
Primary antibodies against clusterin, βAPP, GFAP and markers of activated microglia were 
then applied (see Table 4 for full details) and sections incubated at 37°C for 1hr or at 4°C 
overnight. Sections were washed and secondary Alexa Fluor antibody (goat anti-mouse and 
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goat anti-rabbit, Invitrogen, Paisley, UK) applied for 45 min (in dark). Autofluorescence was 
quenched by incubating the sections in Sudan black for 10min followed by numerous washes 
in phosphate buffered saline before coverslip mounting using Vectashield hard set media with 
DAPI. Sections were visualised using a fluorescent microscope (Zeiss Axiovert S 100, 
Gottingen, Germany) and images captured using ImagePro Express (v6). 
Results 
Expression of clusterin in Alzheimer’s disease 
These cases were confirmed to demonstrate Alzheimer’s disease pathology, showing intense 
immunoreactivity with abnormally phosphorylated tau in plaques, tangles and neuropil 
threads. There was intense immunoreactivity of Aβ in the cortex with all cases showing a 
variable degree of deposition in the meningeal and some cortical blood vessels, consistent 
with amyloid angiopathy. The p62 was positive in some tangles and plaques but pTDP-43 
staining was negative in all cases. βAPP staining showed a variable degree of 
immunoreactivity in the neuritic plaques and scattered positivity in the cortex (See Table 3 
for summary of pathology).  
We were also able to reproduce previously reported expression of clusterin in Alzheimer’s 
disease brain tissue. The clusterin was seen densely aggregated in neuritic plaques and 
immuno-positive neurites were observed (Figure 1A,B). There was granular positivity of 
varying intensity in the glial cells of the white matter (Figure 1C).  
Expression of clusterin in head injury 
Clusterin immunohistochemistry was performed on 32 cases of head injury including 28 
acute head injury (defined as a survival period of 25min up to 46 days post injury (mean age 
46±20yr) and four cases of old head injury with a survival time of 6-10 months (mean age 
27±14yr). 
Clusterin expression was demonstrated in all the cases of head injury but in varying densities 
and cellular location (See Table 1 for summary of pathology). Clusterin immunoreactivity 
was seen predominantly in the white matter and white matter tracts, such as the corpus 
callosum and internal capsule, and less often in the cerebral cortex and grey matter.  
In the cases of acute head injury with a short survival time, clusterin was seen as occasional 
small intra-axonal varicosities or globules, most likely representing sites of axonal 
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dysfunction or disruption. It was detected in cases with a survival time of less than 30 
minutes (Figure 2A) and  appeared to increase in parallel with increased survival time; being 
easily recognised after 60 minutes where more than just occasional deposits were identified. 
The deposits increased in frequency and intensity forming globules, filamentous structures of 
thick and thin filaments in cases with survival of more than one hour and continued to 
increase in intensity up to approximately 24 hours (Figure 2B-E); after which the intensity of 
staining was slightly reduced but still  with many globules or thickened filaments (Figure 2 F, 
G and 3 A-C).  
In the cases with a survival time of 46 and 49 days the axonal  intensity of clusterin staining 
was observed to be much  less, with a lower  density and fainter staining, and in the latter 
case only occasional deposits could be found (Figure 3 D). After this time this pattern was no 
longer seen.  
The clusterin immunoreactivity in the axonal location was similar to the βAPP staining.  
However, clusterin was evident in cases with a survival time of less than 30 minutes, whereas 
βAPP was only identified in this study following survival of 45 minutes or longer. The other 
difference was that clusterin showed granular immunoreactivity in very occcasional glial 
cells after 45 minutes survival. As time progressed there was an increase in the number of 
glial cells staining and in the intensity of staining so as to be more  obvious at  48 hours 
(Figure 2 H,I) and clusterin continued to be moderately over-expressed in survival times of 
several  weeks to  several months (Figures 3 A-D insets and 4); in these later cases, the 
clusterin displayed focal staining, present as cytoplasmic granular deposits in glial cells in the 
corpus callosum and white matter of the cerebral hemispheres and internal capsule. This 
appeared to correlate with the GFAP positive glial cells, thus strongly implying that 
astrocytes were the labelled cells (and also often also applied to strongly labelled S100 
positive cells) (Figure  5). The smaller oligodendrocytes very occasionally showed very mild 
positivity but the vast majority appeared negative.    However, there was no significant 
clusterin deposition in the cerebral cortex or hippocampus. The suggested time lines for 
clusterin immuno-expression is illustrated in Figure 6.  
Immunohistochemistry for Tau, Aβ, pTDP-43 and p62 was negative in all cases of recent and 
old head injury (Table 1). The C5b-9 complement was also negative in all cases, however, 
despite the use of pretreatment  (and confirmed positivity in controls) this may have been a 
reflection of prolonged fixation of the brains in formalin.  
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Clusterin expression in ischaemia and contusions  
We investigated three cases of recent brain ischaemia due to various causes and with survival 
times of between 5-24 hours. These cases showed typical appearances of ischaemia, with red 
shrunken neurones in the cortical deep white matter, hippocampus and Purkinje cells of 
cerebellum. The clusterin showed clear overexpression in the ischaemic neurones and was 
deposited as ill-defined areas with granular and fine filamentous pattern similar to those seen 
in staining with βAPP (Figure 7A). However, this expression appeared to be different from 
the pattern of clusterin and βAPP deposition seen in cases of head injury where the deposits 
were seen as well-defined globules and thickened filaments with no granular background  
In all control cases the staining for clusterin was negative (Figure 7B), as was βAPP, tau, Aβ, 
pTDP43 and p62. CD68 showed an expected increase in the activated microglial cells with 
increased survival time after 48 hours and continued to be intensely over expressed in cases 
of old head injury of 6-10 months (Table 1). In these cases there were also many small 
accumulations of the glial cells consistent with microglial nodules. The main purpose of the 
study was to concentrate on the changes applicable to more diffuse elements of TBI cases. 
Therefore the cases were deliberately chosen in order to reduce the contribution of focal 
elements of trauma. By the very nature of the injury,  however, it  was often  not possible to 
totally eliminate focal damage such as contusions but there was an effort to concentrate on 
cases with at most only  mild contusions (Table 2). The blocks from the test cases were taken 
far from these areas and any other  likely focal pathology. When examined separately, the 
clusterin in  the area of the actual contusions did show immunopositivity with expression in 
astrocytes and some neurones (images not shown). There were also  angulated eosinophilic 
neurones in these regions and some appearing apoptotic.  
All other markers for tau, pTDP-43, Aβ and p62 were negative in cases of acute and old head 
injury 
 
Co- expression  of clusterin with relation to  βAPP 
Double fluorescence microscopy was performed on sections of corpus callosum from three 
head injury cases and three AD cases (labelled
 §
 in Table 1 & 2).  All 3 cases of TBI 
demonstrated adjacent expression but no  co-localisation between clusterin and βAPP 
(survival times of 24-36 hr).   The head injury case with 1-12 hr survival time illustrated a 
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mild scattering of dots of clusterin and β-APP. In contrast, at 24-36 hr there was a significant 
increase in the deposition of both clusterin and βAPP and the deposition had a beaded like 
appearance (Figure 8A). In the AD case adjacent expression  of clusterin with βAPP  was 
observed  in  plaques, however, overall, there was a greater amount of  βAPP  staining  in the 
plaques than was observed for  clusterin  (Figure 8B).  
 
 
Identification of cell-types expressing clusterin 
Using double immunofluorescence cell specific expression was examined in a subset of cases 
using antibodies against astrocytes and activated microglia, alongside those for clusterin. 
Clusterin was not expressed in astrocytes in cases of acute head injury with survival of less 
than 30 minutes, but was evident in astrocytes in old head injury (Figure 8C). In cases of old 
head injury (at least 6 months survival after initial injury) astrocytes had a typical reactive 
morphology.  
  
Using a CD68 antibody as a marker for microglial cells associated with phagocytosis, 
microglia were observed alongside clusterin in head injury cases (Figure 9 A, B ). However, 
there was no co-localisation of clusterin with CD68. Old head injury cases showed similar 
findings to recent head injuries; however, there was somewhat more microglial activation 
present in old head injuries (Figure 9 A,B). In AD sections there were numerous microglia 
evident together with  clusterin, particularly near plaques, however, the microglia  did not 
appear to be  expressing clusterin (images not shown). 
Immunofluorescence was also performed using an HLA-DR clone CR3/43, a marker for 
activated microglia (images not shown).  Findings were similar to the CD68; for head injury 
cases both microglia and clusterin were present, in one case there appeared to be some co-
localisation, which was not observed in either of another two recent head injury cases. In the 
old head injury cases, larger densities of microglia were activated than in acute head injury, 
but there was no co-localisation evident. In the AD cases activated microglia were seen, as 
were clusterin deposits, but again there was no co-localisation seen. 
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Discussion 
In this study we have demonstrated an over-expression of clusterin in TBI in comparison to 
control brain tissue. To our knowledge this has not been demonstrated in human post mortem 
tissue previously and is in keeping with experimental data obtained in animals 
17, 19, 20
. 
We have shown that clusterin is over-expressed very soon after the onset of TBI, suggesting 
that it plays a role in the response to blunt trauma and that it may assist in remodelling and 
modulation of the inflammatory response following this form of brain injury. There was 
staining of clusterin adjacent to  βAPP when examined by double immunofluorescence in 
white matter - which is consistent with overexpression at the site of axonal injury and 
dysfunction.  
Clusterin was observed deposited in the white matter of brains from patients who died from 
head injury as early as  25 minutes after the initial injury. The exact time of death in this type 
of cases is often difficult to ascertain, being dependent on paramedic evaluation. Therefore, it 
was quite possible that death could have occurred even earlier than 25 minutes and that 
clusterin is deposited extremely rapidly after TBI.   Clusterin would appear to be an even 
more sensitive marker for early axonal injury than βAPP 
21
; an important observation for 
medico-legal  practice and may assist in the diagnosis and timing of TBI in patients who died 
quickly after head trauma 
 Like βAPP 
22, 23
, clusterin was also overexpressed in the white matter of brains from patients 
who died from ischaemia without trauma.  Indeed clusterin  has been seen to be 
overexpressed in association with global ischaemia, gliomas, white matter diseases, epileptic 
foci and both chemical and traumatic brain and spinal cord injuries 
5, 17, 24-27
.  Therefore, 
clusterin can be considered as a sensitive marker for axonal damage but not specific as to its 
cause. It may even be involved with axonal regeneration in the peripheral nervous system 
28
 
We found persistent and increasing  immunoexpression of clusterin in the axons, 
corresponding to increasing survival times of the patients after head injury. It appeared to 
reach a maximum expression in 24 hours after which the intensity of clusterin deposits 
appeared to decrease, forming paler-staining  and granular globules and filaments and 
became  much sparser  such that only  a few granular deposits were seen in the brains of  
patients who survived 49 days after head injury. However, this observation has to be 
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considered with caution; firstly because not all the cases had the same degree of head injury 
and hence the amount of clusterin deposition may vary and secondly because the assessment 
was carried out using a semi-quantitative method 
Interestingly, compared with  intra-axonal clusterin deposition in the white matter, we found 
that the deposition of clusterin in occasional  glial cells was seen in brains of patients who 
died  45 minutes after injury and increased in frequency and intensity (as cytoplasmic 
accumulation) after 24 hours before reaching an apparent plateau at 48 hours. Since there was 
co-expression of clusterin and GFAP the vast majority of these glial cells were likely to be 
astrocytes similar to findings following cord injury
25
.   These findings are consistent with the 
function of clusterin as a chaperone protein 
29
. The clusterin deposits in the  astrocytes  
persisted for several months after the head trauma and were demonstrated  intensely in 
patients who survived 9 and 10 months after head injury. Clusterin has a short half-life and it 
may be that in the first  acute phase there is local intra-axonal clusterin protein synthesis 
performed  as a  consequence of axonal shearing (and the local production of stress proteins)  
and   perhaps in an attempt at axonal regeneration which has been shown to occur in 
peripheral nerves
28, 30, 31
.   After this regeneration  has been partially achieved or prevented  
this aspect of clusterin production  is reduced and replaced by astrocytic clusterin protection  
perhaps  to  aid  protection against inflammatory mediators and toxic proteins
25, 30, 31
.    This 
different location and timing of expression of clusterin, first at the site of axonal injury soon 
after head trauma and later accumulating  in astrocytes in older head injury,  could be seen to 
be a two track response and would  be similar but not identical  to the  biphasic increase in 
protein concentration as reported in experimental head injury. Iwata et al., demonstrated an 
increase in protein deposition and number of cells immunoreactive for clusterin, initially 
peaking in 2 days, returning to baseline level by  2 weeks then gradually increasing 
throughout  6 months post trauma 
17
. Our study did show a decrease in the axonal 
immunoexpression of clusterin to a baseline level  between 6 weeks and 6 months, but the 
astroglial expression once seen was maintained even after 6 months. It could be noted that 
there were no cases with a survival of between 6 weeks and 6 months in our cohort, and at 
least theoretically there may have been a decrease and subsequent recovery of astrocytic 
expression within this time period but it would appear unlikely.   The findings also differ 
from the  rat model described in that  Iwata et al. described accumulation of  Aβ alongside 
clusterin (between 1-6 months), and this was not present in our study 
17
.   This gradual 
increase of clusterin in astrocytes in our study occurred with a mounting long-term post-
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traumatic neuro-inflammatory process. The latter was clearly demonstrated in our post-
mortem tissue, with an increase in the number of microglia cells (as demonstrated with CD68 
antibody) after 24 hours, which became more obvious after 48 hours and persisted to a high 
level of expression even in patients surviving 10 months after head injury. These findings 
further support the evidence that clusterin may play an active role in modulating the 
neuroinflammatory response and possibly has a protective role even several months after 
head injury. Previous research has demonstrated a long term neuroinflammatory response by 
microglia and infiltrating macrophages after head injury 
13
;  these cells are the source of 
cytokines and this may in turn incite more activation of astrocytes,  and increase  S100 
protein  and then induce  further activation of microglial cells hence  enabling a sustained 
inflammatory response.  
It is possible that the accumulated clusterin in the white matter astrocytes may not only have 
a role in modulating the increasing post trauma neuroinflammation but may also represent a 
protective process (or at least a better reparative process) by lipoproteins after head injury.  
Imhof et al., proposed that sustained increase of clusterin expression in astrocytes improved 
structural recovery after ischaemic insults since the restoration process was clearly slower 
and less successful in clusterin knock down mice compared to that seen in wild type 
19
.  
There is also supportive evidence from patients with clusterin (CLU) gene mutations that the 
protein is important in maintaining white matter structural integrity
32
.  As we have confirmed 
in this study, clusterin was typically present in neuritic plaques and neuropil threads but 
rarely in primitive plaques and neurofibrillary tangles 
33
. It has been reported that clusterin 
can target and act as a chaperone for amyloid peptides and mediate their clearance but later 
enhances the formation of the plaques when the amyloid is fibrillized and aggregated. 
Interestingly,  the absence of  astrocytic clusterin   in association with Alzheimer disease 
plaques may be due to some mutual regulatory process
34, 35
. There appears a similar lack of 
astrocytic clusterin expression in the vicinity of prion protein plaques in experimental prion 
disease
36
.   Clusterin can  inhibit the complement activation and mask the misfolded protein 
to prevent excessive inflammation and neuronal death, although the findings in the injured 
nervous system are sometimes contradictory as exemplified by our findings (allowing for the 
caveat already stated above)  
1, 37, 38
. It is therefore possible that clusterin may play a 
protective role after trauma by binding to Aβ and suppressing its accumulation. This process 
may explain the lack of any Aβ accumulation in our head injury cases despite the presence of 
a high level of βAPP deposition.  
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There are several reports of increasing risk of dementia and Alzheimer’s disease after TBI 
14, 
39
. However, other epidemiological studies have failed to confirm such association 
40
. It 
appears that there are many unanswered questions resulting from these largely retrospective 
and complex observational studies about the link between a single TBI and dementia and its 
actual prevalence. The pathology and clinical manifestation of   chronic traumatic 
encephalopathy (CTE) and its relation to repeated minor trauma is well established, e.g. that 
seen in boxers, military veterans and American football players. Pathologically it is 
characterised by abnormal phosphorylated tau deposition at the depth of sulci and around 
blood vessels in early stages, involving other regions in the brain in more advance stages in 
addition to TDP-43 pathology 
41-43
. On the other hand the  “single episode TBI” associated 
dementia is often thought to be Alzheimer’s type of dementia 
44
, however, this is not 
absolutely proven and the association appears to be more complex 
 
In contrast to the accumulation of clusterin in the astrocytes of the white matter in our cases 
of old head injury, we did not find any significant accumulation in the neurons.  The stains 
for tau, pTDP-43, Aβ and p62 were negative in all our cases of head injury, including those 
with several months’ survival; which may exclude the possibility of early Alzheimer’s 
disease or TDP-43 related pathology. These findings suggest either that there is no, or only a 
minor indirect or as yet unexplained complex role of clusterin in post-traumatic Aβ plaques 
and Alzheimer’s disease changes.  Therefore, the question as to how  diffuse white matter  
axonal  damage could  later  lead to a neurodegenerative disease defined predominantly by 
cortical neuronal pathology remains  unanswered.  The investigation of clusterin  
immunoexpression  in a cohort of well-established chronic traumatic encephalopathy cases 
(following repeated low level head injury)   compared with Alzheimer’s disease cases (with 
and without a pre-existing history of TBI) will therefore  form the basis of further studies. 
In summary, this study  not only reveals axonal clusterin expression to be an  early response 
to head injury  but also indicates that the protein continues to be expressed in astrocytes  
several months after the trauma.   There is  evidence to suggest that clusterin  is involved in 
modulating the inflammatory response. Understanding the role clusterin plays in the 
pathology of  TBI could lead to  possible therapeutic interventions. Further studies  are 
needed  to authenticate these findings and to investigate the possible relationship between      
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clusterin expression  in cases of repeated mild head injury, old head injury of several years’ 
survival and  neurodegenerative conditions such as chronic traumatic encephalopathy.  
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Legends to Figures  
 
 
Figure 1:   Clusterin expression in Alzheimer’s disease  cerebral tissue. 
Immunohistochemistry demonstrates Clusterin within neuritic plaques (A), neuropil threads 
(arrowed - B) and glial cells (arrowed - C). Scale bar represents 20µm. 
Figure 2: Clusterin expression shown in  traumatic brain injury (TBI) cases with increasing 
time of survival from initial head injury. Clusterin is first seen to deposit as axonal globules, 
becoming most visible after several hours as globules and filaments. After 24 hours filaments 
are still numerous but intensity lessens. Glial expression becomes more prominent as survival 
time increases  (up to 48 hours).  (panels H & I show glial expression), insets show glial cells 
at higher magnification.. Scale bar represents 20µm (A-C, F, H, I) and 50µm (D, E, G)  and   
15µm (H inset and I inset). 
Figure 3: Clusterin expression demonstrated in TBI cases with a survival time of several 
days. Inset panels show glial expression. Scale bar represents 20µm (main images) and 50µm 
(insets). 
Figure 4: Clusterin expression demonstrated in old head injury cases with a survival time of 
over 6 months. Strong glial cell expression as cytoplasmic deposits can be seen within the 
white matter. Scale bar represents 20µm (A, B, D) and 50µm (C). 
Figure 5: Adjacent  sections from white matter in a case of old head injury with a survival of  
9 months and showing the cellular  immunoexpression of  clusterin (A), GFAP (B) and S100 
(C and inset). Note the cells expressing clusterin (arrows) appear to be very similar in shape 
and  size to those reactive astrocytes positive for GFAP (arrows), and those astrocytes 
strongly expressing S100 (arrows), the smaller rounded oligodendrocytes (arrowheads) not 
staining for clusterin or GFAP and weaker for S100.  Scale bar represents 50 µm (A-C), and 
15µm (C inset).  
Figure 6: Schematic diagram illustrating the time line after survival from head injury and the 
relative immuno-expression of clusterin in axons (A) and astrocytic cells (B).   
Figure 7: Clusterin expression in an ischaemia case, showing a granular and fine filamentous 
pattern (A) (white matter of the frontal lobe) and in a control case, showing no visible 
expression (B). Scale bar represents 50µm. 
Figure 8: (A) Double immunofluorescence of clusterin (red) and βAPP (green) within an 
acute head injury case demonstrates areas of  adjacent expression (indicated with arrows) as 
well as deposits of clusterin and βAPP alone. (B) Expression of both clusterin and βAPP 
within plaques can be seen in an AD case (arrows). (C) There is co-localisation of clusterin 
and GFAP within astrocytes (arrows) in an old head injury case, but this is not evident in 
acute head injury. Scale bar represents 30µm.  
Figure 9: A and B:  There is  no co-localisation of clusterin (red), and microglia (CD68 - 
green) in any of the cases, however, cases of old head injury (A) showed somewhat increased 
microglial activation compared to acute head injury (B). Scale bar represents 30µm.  
 
Page 19 of 34
http://www.blackwellpublishing.com/neu
Neuropathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
 
 
Case Age/ 
sex 
Survival 
period 
 
Clusterin βAPP CD68* Tau Aβ TDP43 p62 
Axons Glial Axons Glial 
HI1 § 34 M 25 min + -ve -ve -ve -ve -ve -ve -ve -ve 
HI2 § 30 M 30 min + -ve -ve -ve -ve -ve -ve -ve -ve 
HI3 ? F < 30 min + -ve -ve -ve -ve -ve -ve -ve -ve 
HI4 30 M < 30 min + -ve -ve -ve -ve -ve -ve -ve -ve 
HI5 § 41 M 45 min ++ + + -ve -ve -ve -ve -ve -ve 
HI6 30 M 50 min + + + -ve -ve -ve -ve -ve -ve 
HI7 43 F < 60 min + + + -ve -ve -ve -ve -ve -ve 
HI8 80 M < 60 min + + + -ve -ve -ve -ve -ve -ve 
HI9 25 M < 60 min ++ + ++ -ve -ve -ve -ve -ve -ve 
HI10 74 M 3-5 h +++ + +++ -ve -ve -ve -ve -ve -ve 
HI11 83 F 4 h +++ + +++ -ve -ve -ve -ve -ve -ve 
HI12 52 F 6 h ++++ ++ ++++ -ve -ve -ve -ve -ve -ve 
HI13 24 M 9 h ++++ ++ ++++ -ve -ve -ve -ve -ve -ve 
HI14 44 M 10 h ++++ ++ ++++ -ve -ve -ve -ve -ve -ve 
HI15 50 M 16 h +++++ ++ +++++ -ve -ve -ve -ve -ve -ve 
HI16 53 M 21 h +++++ ++ +++++ -ve -ve -ve -ve -ve -ve 
HI17 21 M 24 h +++++ ++ +++++ -ve + -ve -ve -ve -ve 
HI18 43 M 39 h +++ +++ +++ -ve + -ve -ve -ve -ve 
HI19 60 M 40 h +++ +++ +++ -ve ++ -ve -ve -ve -ve 
HI20 29 M 48 h +++ +++ +++ -ve ++ -ve -ve -ve -ve 
HI21 25 F 48 h +++ +++ +++ -ve ++ -ve -ve -ve -ve 
HI22 72 M 8 d +++ ++ ++ -ve +++ -ve -ve -ve -ve 
HI23 61 M 14 d +++ +++ ++ -ve ++++ -ve -ve -ve -ve 
HI24 55 M 14 d +++ +++ ++ -ve ++++ -ve -ve -ve -ve 
HI25 § 21 M 22 d +++ +++ ++ -ve ++++ -ve -ve -ve -ve 
HI26 16 M 27 d +++ +++ ++ -ve ++++ -ve -ve -ve -ve 
HI27 59 M 46 d ++ +++ + -ve ++++ -ve -ve -ve -ve 
HI28 76 F 49 d + +++ + -ve ++++ -ve -ve -ve -ve 
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Case Age/ 
sex 
Survival 
period 
 
Clusterin βAPP CD68* Tau Aβ TDP43 p62 
Axons Glial Axons Glial 
HI29 41 M 6 mo -ve +++ -ve -ve +++++ -ve -ve -ve -ve 
HI30 § 22 M 10 mo -ve +++ -ve -ve +++++ -ve -ve -ve -ve 
HI31 10 M 9 mo -ve +++ -ve -ve +++++ -ve -ve -ve -ve 
HI32 § 35 M 7 mo -ve ++ -ve -ve +++++ -ve -ve -ve -ve 
 
Table 1: Case details and neuropathological results for Head Injury cases 
+ occasional (1-2 per area), ++ few (3-6 per area), +++ many (7-10 per area), ++++ several (11-15 per 
area), +++++ numerous (more than 16 per area)   -ve –No staining identified 
CD68*: The quantification of CD68 is compared with control cases, which usually show a base line 
number of microglial cells. The number of pluses reflect, + slight, ++ more than slight, +++ moderate 
with microglial nodules, ++++ marked with microglial nodules and +++++ very marked increase of 
microglial cells with many microglial nodules. 
 §-Also used in  double immunofluorescence studies 
F-Female, M-Male, min-minutes, h-hours, d-days, mo-months 
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Number Brain 
swelling 
Contusions SAH SDH or EDH Small 
haemorrhage in 
corpus callosum 
Haemorrhage 
in brainstem 
Ischaemia Diagnosis 
HI1 - + frontal + - + - 
+ 
TBI 
HI2 - - - - - - - TBI 
HI3 - - - - - - - TBI 
HI4 - + frontal + - + - - TBI 
HI5 - + fronto- temporal + - + + - TBI 
HI6 - + fronto- temporal + - + - - TBI 
HI7 - - - - - + -  TBI 
HI8 - - + - + + - TBI 
HI9 - - - - + - - TBI 
HI10 - - - - + - - TBI 
HI11 - + frontal + - - - + (hippo) TBI 
HI12 - + frontal - - + -  TBI 
HI13 +  + frontal + - - - 
+ 
TB 
HI14 - - + - + - + (hippo) TBI 
HI15 + + fronto- temporal + - - - + (cortex) TBI 
HI16 +  + fronto- temporal + - + - + (cortex) TBI 
HI17 +  + fronto- temporal + - - + + (cortex) TBI 
HI18 - - + - + - - TBI 
HI19 +  + fronto  temporal + - - + + (cortex)  TBI 
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Number Brain 
swelling 
Contusions SAH SDH or EDH Small 
haemorrhage in 
corpus callosum 
Haemorrhage 
in brainstem 
Ischaemia Diagnosis 
HI20 - + fronto- temporal + - - + + (cortex) TBI 
HI21 +  +  frontal + + SDH - - + (cortex) TBI 
HI22 - - + - + - + (cortex) TBI 
HI23 + +  frontal + +  SDH - - + (cortex) TBI 
HI24 + + fronto-temporal + + EDH - - + TBI 
HI25 +  + frontal + + SDH + - 
+ 
TBI 
HI26 + - - - + - + TBI 
HI27 + - + + SDH  - 
+ 
TBI 
HI28 - - + IV bleed + - + TBI 
HI29  - - + (old) +  old  SDH  - - - Old TBI 
HI30  - +  fronto-temporal + (old) + old SDH - - 
- 
Old TBI 
HI31  - - + (old) + old SDH - - +  (cortex)  Old TBI 
HI32  - - + (old) + old SDH - - - Old TBI 
 
 
Table 2 – Illustrating the co-existing focal cerebral pathology in the traumatic brain injury cases.  
 
 
SAH-subarchnoid haemorrhage, EDH-extra dural haemorrhage, SDH, subdural haemorrhage, IV intraventricular,  TBI- traumatic brain injury, 
Hippo-hippocampus 
 
+ - mild ( in SAH-thin film; EDH <20 mls; SDH < 30 mls,; swelling -  mild cerebral sulcal narrowing- no herniation) 
 
-  Negative/not present    
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Table 3: Case details and neuropathological results from Alzheimer’s disease, ischaemia and 
control cases.   
For Clusterin,  βAPP (Isch cases)   : + occasional (1-2 per area), ++ few (3-6 per area), +++ many (7-10 
per area), ++++ several (11-15 per area), +++++ numerous (more than 16 per area)   -ve –No staining 
identified 
For βAPP (AD cases), Tau,  Aβ, TDP-43 and p62:   +- minimal positivity, ++ few/mild, +++ moderate, 
++++ severe/extensive positivity,     -ve –No staining identified 
 
§- Also used for double immunofluorescence studies  
 
No 
 
Age/ 
sex 
Diagnosis/Cause of 
Death 
Clusterin βAPP 
 
Tau Aβ TDP43 p62 
Axons Glial 
AD1 § 86F Alzheimer’s Disease 
(Braak stage VI) 
-ve +++ +++ ++++ ++++ -ve ++ 
AD2 § 86F Alzheimer’s Disease 
(Braak stage V1) 
-ve ++ +++ ++++ ++++ -ve ++ 
AD3 § 92M Alzheimer’s Disease 
(Braak stage V1) 
-ve +++ +++ ++++ ++++ -ve ++ 
AD4 72M Alzheimer’s Disease -ve +++ +++ ++++ ++++ -ve ++ 
Isch1 37M Hypovolemic shock +++ ++ +++ -ve -ve -ve -ve 
Isch2 63M Cardiac arrest +++ ++ +++ -ve -ve -ve -ve 
Isch3 31F Intestinal bleeding +++ ++ ++++ -ve -ve -ve -ve 
C1 47M Subarachnoid 
haemorrhage 
-ve -ve -ve -ve -ve -ve -ve 
C2 28M Hypovolemic shock -ve -ve -ve -ve -ve -ve -ve 
C3 54M Subarachnoid 
haemorrhage 
-ve -ve -ve -ve -ve -ve -ve 
C4 24M Cardiac arrest -ve -ve -ve -ve -ve -ve -ve 
C5 36M Sudden unexplained 
death – no evidence 
of brain pathology 
-ve -ve -ve -ve -ve -ve -ve 
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Primary Antibody Type Manufacturer Dilution 
Clusterin (ApoJ) Polyclonal AbCam  1:500 
Clusterin (ApoJ) Monoclonal Santa Cruz  1:500 
βAPP Monoclonal Chemicon 1,1000 
GFAP Polyclonal DAKO  1:2000 
CD68  Monoclonal DAKO  1:50 
HLA-DR (CR3/4) Monoclonal DAKO 1:100 
 
Table 4: details of antibodies used in double immunofluorescence protocols. 
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Figure 1:   Clusterin expression in Alzheimer’s disease  cerebral tissue. Immunohistochemistry demonstrates 
Clusterin within neuritic plaques (A), neuropil threads (arrowed - B) and glial cells (arrowed - C). Scale bar 
represents 20µm.  
52x13mm (300 x 300 DPI)  
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Figure 2: Clusterin expression shown in  traumatic brain injury (TBI) cases with increasing time of survival 
from initial head injury. Clusterin is first seen to deposit as axonal globules, becoming most visible after 
several hours as globules and filaments. After 24 hours filaments are still numerous but intensity lessens. 
Glial expression becomes more prominent as survival time increases  (up to 48 hours).  (panels H & I show 
glial expression), insets show glial cells at higher magnification. Scale bar represents 20µm (A-C, F, H, I) 
and 50µm (D, E, G)  and   15µm (H inset and I inset).  
74x56mm (300 x 300 DPI)  
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Figure 3: Clusterin expression demonstrated in TBI cases with a survival time of several days. Inset panels 
show glial expression. Scale bar represents 20µm (main images) and 50µm (insets).  
77x60mm (300 x 300 DPI)  
 
 
Page 28 of 34
http://www.blackwellpublishing.com/neu
Neuropathology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review
  
 
 
Figure 4: Clusterin expression demonstrated in old head injury cases with a survival time of over 6 months. 
Strong glial cell expression as cytoplasmic deposits can be seen within the white matter. Scale bar 
represents 20µm (A, B, D) and 50µm (C).  
77x60mm (300 x 300 DPI)  
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Figure 5: Adjacent  sections from white matter in a case of old head injury with a survival of  9 months and 
showing the cellular  immunoexpression of  clusterin (A), GFAP (B) and S100 (C and inset). Note the cells 
expressing clusterin (arrows) appear to be very similar in shape and  size to those reactive astrocytes 
positive for GFAP (arrows), and those astrocytes strongly expressing S100 (arrows), the smaller rounded 
oligodendrocytes (arrowheads) not staining for clusterin or GFAP and weaker for S100.  Scale bar represents 
50 µm (A-C), and 15µm (C inset).  
54x14mm (300 x 300 DPI)  
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Figure 6: Schematic diagram illustrating the time line after survival from head injury and the relative 
immuno-expression of clusterin in axons (A) and astrocytic cells (B).    
150x112mm (300 x 300 DPI)  
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Figure 7: Clusterin expression in an ischaemia case, showing a granular and fine filamentous pattern (A) 
(white matter of the frontal lobe) and in a control case, showing no visible expression (B). Scale bar 
represents 50µm.  
56x21mm (300 x 300 DPI)  
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Figure 8: (A) Double immunofluorescence of clusterin (red) and βAPP (green) within an acute head injury 
case demonstrates areas of  adjacent expression (indicated with arrows) as well as deposits of clusterin and 
βAPP alone. (B) Expression of both clusterin and βAPP within plaques can be seen in an AD case (arrows). 
(C) There is , co-localisation of clusterin and GFAP within astrocytes (arrows) in an old head injury case, but 
this is not evident in acute head injury. Scale bar represents 30µm.  
112x84mm (300 x 300 DPI)  
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Figure 9: A and B:  There is  no co-localisation of clusterin (red), and microglia (CD68 - green) in any of the 
cases, however, cases of old head injury (A) showed somewhat increased microglial activation compared to 
acute head injury (B). Scale bar represents 30µm.  
55x20mm (300 x 300 DPI)  
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